The Sunday Times reports that GlaxoSmithKline (GSK) have integrated Owlstone Medical's Breath Biopsy platform into the clinical development programme of one of the novel drug candidates in their respiratory disease pipeline. The Phase II clinical trial will assess whether the right patient for the right treatment can be identified, as well as assessing the treatment effects of danirixin, a drug candidate for chronic obstructive pulmonary disease (COPD). The deal with GSK is a further important step in our strategy to bring Breath Biopsy to precision medicine applications through our Biomarker Services.
You can read the Sunday Times article below:
Breath Test aids GSK trial
by Sabah Meddings
Glaxo Smith Kline is to use a "cancer breathalyser" to screen patients for its latest trial of a new drug to treat a respiratory disease.
The drugs giant has teamed up with Owlstone Medical, a Cambridge company founded by entrepreneur Billy Boyle, who developed the technology after his wife died of colon cancer at 36.
Glaxo will use Boyle's breathalyser to identify not signs of cancer but patients who will respond to its drugs, by collecting so-called volatile organic compounds in their breath. By analysing these samples, Glaxo can screen patients before they take part in a phase II clinical trial of a new drug known as danirixin.
Ruth Tal-Singer, senior fellow in respiratory research and development at Glaxo, said the tool would identify patients who could "benefit most" from its medicines.
If you want to learn more about how Owlstone Medical's Breath Sampling and Analysis technology and Services are being utilized in early detection and precision medicine, why not download our free ebook: Breath Biopsy: The Complete Guide?